webinar register page

Webinar banner
SU2C Gastric Cancer Interception Research Team: Early Detection and Interception of Diffuse and Intestinal Gastric Cancer


Oct 15, 2021 10:31 AM

Webinar logo
* Required information
**Disclaimer: The webinar provided by Hope for Stomach Cancer is for informational and supportive purposes only. They are not intended to be substitutes for professional medical advice, diagnosis, or treatment. Hope for Stomach Cancer does not recommend or endorse any specific medical providers, treatments, or products even though they may be mentioned in the webinar. Additionally, the Doctors participating in this webinar series are volunteers and they do not receive any compensation for their involvement. The comments and remarks that are made as part of this webinar are to be considered as information only. Always seek the advice of your physician or other qualified medical provider with any questions you may have regarding your medical condition or any information you found in this webinar.


Andrew T. Chan, MD, MPH
Gastroenterologist, Professor of Medicine, Immunology & Infectious Diseases, Chief of Clinical & Translational Epidemiology @Massachusetts General Hospital | Harvard Medical School
Dr. Chan is an international expert in cancer prevention and interception, leading several seminal studies examining the role of aspirin, diet, and the gut microbiome on cancer risk.
Dr. Sandra Ryeom
Associate Professor, Associate Dean of Post-doctoral Affairs andand new Master’s degree program @Columbia University Medical Center (CUMC) in the Division of Surgical Sciences and Department of Surgery
Dr. Ryeom’s lab utilizes genetically engineered mouse models and molecular and cellular biological approaches to investigate the initiation and metastatic progression of cancer in many different organs including gastric cancer.
David A. Drew, PhD
Director of Biobanking for Clinical & Translational Epidemiology, Instructor of Medicine in the Division of Gastroenterology @Massachusetts General Hospital | Harvard Medical School
Dr. Drew’s laboratory focuses on translating epidemiological and clinical observations into biological mechanisms of disease that may be leveraged for precision medicine biomarker development and leads several translational clinical studies focused on the prevention and interception of gastrointestinal cancers, including gastric cancer.